AR065206A1 - Compuestos de anillo fusionado - Google Patents
Compuestos de anillo fusionadoInfo
- Publication number
- AR065206A1 AR065206A1 ARP080100508A ARP080100508A AR065206A1 AR 065206 A1 AR065206 A1 AR 065206A1 AR P080100508 A ARP080100508 A AR P080100508A AR P080100508 A ARP080100508 A AR P080100508A AR 065206 A1 AR065206 A1 AR 065206A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- ring
- ylidene
- group
- conr1as
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
La presente provee un agente para la prevencion o el tratamiento de diabetes, que tiene una accion hipoglucémica superior, y está asociado con menores efectos colaterales tales como aumento de peso corporal, y similares. Agente farmacéutico y uso. Reivindicacion 1: Un compuesto representado por la formula (1') en donde el anillo A y el anillo B son iguales o diferentes y cada uno es un monociclo de 5 a 7 miembros opcionalmente sustituido; el anillo D' es un heterociclo aromático monocíclico de 5 miembros opcionalmente sustituido, en donde Y' es N o C; X es un espaciador que tiene 1 a 4 átomos en la cadena principal; y W es un grupo representado por -CONR1aS(O)mR2, -CONR1aS(O)mR2, -CONR1aCONR1cR2, -CONR1aS(O)mNR1cR2, - NR1bCONR1aS(O)mR2, -NR1bS(O)mNR1aCOnR2, -S(O)mNR1aCOnR2, -S(O)mNR1aCONR1cR2, -OCONR1aS(O)mR2, -OCONR1aS(O)mNR1cR2, -ONR1aCOnR2, -OCONR1cR2, o -ONR1aCONR1cR2 en donde R1a y R1b son iguales o diferentes y cada uno es un átomo de hidrogeno o un grupo alquilo C1-6; R1c es un átomo de hidrogeno, un grupo alquilo C1-6 o un grupo alcoxi C1-6; R2 es un átomo de hidrogeno, un grupo hidrocarbonado opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido; y m y n son iguales o diferentes y cada uno es un numero entero de 1 o 2, o un grupo heterocíclico de 5 o 6 miembros que contiene NH, que está opcionalmente sustituido, con la condicion de que 1) cuando el anillo D' es un imidazol sustituido, entonces W no sea 2-amino-1H- imidazol-5-ilo, 1H-imidazol-2-ilo, 3,5-dimetil-1H-pirazol-4-ilo y piperazin-1-ilo; 2) cuando el anillo D' es un pirazol sustituido, y X es - CH=, entonces W no sea 4-oxo-2-tioxo-1,3-tiazolidin-5-ilideno, 5-oxo-2-tioxoimidazolidin-4-ilideno opcionalmente sustituido con grupo(s) fenilo, 3-metil-5-oxo-1,5-dihidro-4H-pirazol-4-ilideno, 2,4,6- trioxotetrahidropirirnidin-5(2H)-ilideno y 4,6-dioxo-2-tioxotetrahidropirimidin-5(2H)-ilideno; y 3) se excluya 5-(6-metoxi-2-naftil)-1-(pirrolidin-2- ilmetil)-1H-1,2,3-triazol, o una de sus sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007031221 | 2007-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065206A1 true AR065206A1 (es) | 2009-05-20 |
Family
ID=39523585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100508A AR065206A1 (es) | 2007-02-09 | 2008-02-06 | Compuestos de anillo fusionado |
Country Status (21)
Country | Link |
---|---|
US (2) | US20110009384A1 (es) |
EP (1) | EP2118066A1 (es) |
JP (1) | JP2010517935A (es) |
KR (1) | KR20090106660A (es) |
CN (1) | CN101646653A (es) |
AR (1) | AR065206A1 (es) |
AU (1) | AU2008215490A1 (es) |
BR (1) | BRPI0807014A2 (es) |
CA (1) | CA2677736A1 (es) |
CL (1) | CL2008000377A1 (es) |
CR (1) | CR10991A (es) |
DO (1) | DOP2009000202A (es) |
EA (1) | EA200970746A1 (es) |
EC (1) | ECSP099618A (es) |
IL (1) | IL200114A0 (es) |
MA (1) | MA31189B1 (es) |
MX (1) | MX2009008103A (es) |
PE (1) | PE20090068A1 (es) |
TN (1) | TN2009000312A1 (es) |
TW (1) | TW200838515A (es) |
WO (1) | WO2008099794A1 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
TW201014850A (en) | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
EP2373165B1 (en) * | 2008-11-14 | 2013-10-30 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivaties |
US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
EP2440541A1 (en) | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
IN2012DN00954A (es) | 2009-07-28 | 2015-04-10 | Takeda Pharmaceutical | |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP5693611B2 (ja) | 2010-04-27 | 2015-04-01 | 武田薬品工業株式会社 | 二環性化合物 |
GEP20146195B (en) | 2010-06-16 | 2014-11-10 | Takeda Pharmaceuticals Co | Crystal of amide compound |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
EP2617726A4 (en) | 2010-09-17 | 2014-05-14 | Takeda Pharmaceutical | DIABETES THERAPEUTIC |
US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
KR20140015371A (ko) | 2011-02-17 | 2014-02-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 광학적 활성 디히드로벤조푸란 유도체 제조 방법 |
CN102816205B (zh) * | 2011-06-09 | 2014-12-10 | 中国科学院上海生命科学研究院 | β抑制蛋白1、其片段及其应用 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA2853221A1 (en) | 2011-10-24 | 2013-05-02 | Tohru Yamashita | Bicyclic compound |
WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
WO2013105676A1 (en) | 2012-01-12 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122028A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
JP6106179B2 (ja) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168759A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168760A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
US9346762B2 (en) | 2012-05-18 | 2016-05-24 | Sanofi | Pyrazole derivatives and their use as LPAR5 antagonists |
EP2850062B1 (en) | 2012-05-18 | 2017-07-19 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
CA2874820C (en) | 2012-06-05 | 2020-06-09 | Takeda Pharmaceutical Company Limited | Disintegrable and preservation stable solid preparation |
JP2015127299A (ja) | 2012-07-19 | 2015-07-09 | 武田薬品工業株式会社 | 固形製剤 |
US9643950B2 (en) | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
JP6247697B2 (ja) | 2013-03-14 | 2017-12-13 | 武田薬品工業株式会社 | スピロアゼチジンイソキサゾール誘導体及びそのsstr5アンタゴニストとしての使用 |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2015005489A1 (en) | 2013-07-09 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015020184A1 (ja) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | 芳香環化合物 |
JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
CN107567443B (zh) | 2014-12-24 | 2023-04-28 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
US10445126B2 (en) * | 2017-02-21 | 2019-10-15 | Red Hat, Inc. | Preloading enhanced application startup |
JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
CA3058578A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Aromatic compound |
AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
US10471045B2 (en) * | 2017-07-21 | 2019-11-12 | The University Of Hong Kong | Compounds and methods for the treatment of microbial infections |
US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
US20200407340A1 (en) * | 2018-03-02 | 2020-12-31 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
MX2020009950A (es) | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Moduladores de receptores acoplados a proteina g. |
WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
US20220135638A1 (en) | 2018-09-24 | 2022-05-05 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
JP2022500483A (ja) | 2018-09-24 | 2022-01-04 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
MX2022011816A (es) | 2020-03-25 | 2022-10-10 | Takeda Pharmaceuticals Co | Dosificacion qd de compuestos peptidicos agonistas del receptor de gip y sus usos. |
KR20220157409A (ko) | 2020-03-25 | 2022-11-29 | 다케다 야쿠힌 고교 가부시키가이샤 | Gip 수용체 작용제 펩티드 화합물 및 이의 용도 |
BR112023023559A2 (pt) | 2021-05-13 | 2024-02-06 | Carmot Therapeutics Inc | Moduladores de receptores acoplados à proteína g |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
US6413994B1 (en) * | 1999-02-22 | 2002-07-02 | The Salk Institute For Biological Studies | Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
CA2315736A1 (en) * | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
RU2238937C2 (ru) * | 1998-12-24 | 2004-10-27 | Фудзисава Фармасьютикал Ко., Лтд. | Производные имидазола, фармацевтическая композиция и способ профилактики и/или лечения на их основе |
ES2318649T3 (es) * | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
WO2003099793A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
US7317032B2 (en) * | 2003-09-02 | 2008-01-08 | Bristol-Myers Squibb Co. | Imidazolyl inhibitors of 15-lipoxygenase |
US7432271B2 (en) * | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
WO2006075955A1 (en) * | 2005-01-13 | 2006-07-20 | Astrazeneca Ab | Pyrazolyl acylsulfonamide derivatives as endothelin converting enzyme inhibitors and useful in the treatment of chronic obstructive pulmonary disease |
-
2008
- 2008-02-05 MX MX2009008103A patent/MX2009008103A/es unknown
- 2008-02-05 EA EA200970746A patent/EA200970746A1/ru unknown
- 2008-02-05 BR BRPI0807014-8A patent/BRPI0807014A2/pt not_active IP Right Cessation
- 2008-02-05 CN CN200880010565A patent/CN101646653A/zh active Pending
- 2008-02-05 US US12/449,388 patent/US20110009384A1/en not_active Abandoned
- 2008-02-05 TW TW097104515A patent/TW200838515A/zh unknown
- 2008-02-05 WO PCT/JP2008/052217 patent/WO2008099794A1/en active Application Filing
- 2008-02-05 AU AU2008215490A patent/AU2008215490A1/en not_active Abandoned
- 2008-02-05 KR KR1020097018732A patent/KR20090106660A/ko not_active Application Discontinuation
- 2008-02-05 JP JP2009528428A patent/JP2010517935A/ja not_active Withdrawn
- 2008-02-05 CA CA002677736A patent/CA2677736A1/en not_active Abandoned
- 2008-02-05 EP EP08704537A patent/EP2118066A1/en not_active Withdrawn
- 2008-02-06 PE PE2008000266A patent/PE20090068A1/es not_active Application Discontinuation
- 2008-02-06 US US12/068,442 patent/US20080194617A1/en not_active Abandoned
- 2008-02-06 AR ARP080100508A patent/AR065206A1/es unknown
- 2008-02-06 CL CL200800377A patent/CL2008000377A1/es unknown
-
2009
- 2009-07-28 IL IL200114A patent/IL200114A0/en unknown
- 2009-07-30 TN TNP2009000312A patent/TN2009000312A1/fr unknown
- 2009-08-07 DO DO2009000202A patent/DOP2009000202A/es unknown
- 2009-08-13 MA MA32174A patent/MA31189B1/fr unknown
- 2009-08-24 CR CR10991A patent/CR10991A/es not_active Application Discontinuation
- 2009-09-08 EC EC2009009618A patent/ECSP099618A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TN2009000312A1 (en) | 2010-12-31 |
EA200970746A1 (ru) | 2010-02-26 |
MA31189B1 (fr) | 2010-02-01 |
TW200838515A (en) | 2008-10-01 |
DOP2009000202A (es) | 2009-09-15 |
CL2008000377A1 (es) | 2008-08-22 |
JP2010517935A (ja) | 2010-05-27 |
BRPI0807014A2 (pt) | 2014-04-22 |
AU2008215490A1 (en) | 2008-08-21 |
MX2009008103A (es) | 2009-08-18 |
PE20090068A1 (es) | 2009-02-25 |
WO2008099794A1 (en) | 2008-08-21 |
ECSP099618A (es) | 2009-10-30 |
IL200114A0 (en) | 2010-04-15 |
US20110009384A1 (en) | 2011-01-13 |
CA2677736A1 (en) | 2008-08-21 |
EP2118066A1 (en) | 2009-11-18 |
KR20090106660A (ko) | 2009-10-09 |
US20080194617A1 (en) | 2008-08-14 |
AU2008215490A2 (en) | 2009-09-24 |
CR10991A (es) | 2009-10-06 |
CN101646653A (zh) | 2010-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065206A1 (es) | Compuestos de anillo fusionado | |
CO5570666A2 (es) | Agente para prevenir o tratar neuropatia | |
NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
NO20063866L (no) | 1,3,5-trisubstituerte 4,5-di hydro-1 H-pyrazolderivater med CB1-antagonistisk aktivitet. | |
AR075238A1 (es) | Compuestos de piridazinona | |
EA201070323A1 (ru) | Замещенное производное пиразола | |
RU2007139634A (ru) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения | |
UA94424C2 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | |
EA201000619A1 (ru) | Новые производные имидазола | |
MX2007000016A (es) | Derivados de pirazol. | |
PE20071318A1 (es) | Derivados nuevos de urea ciclica, su preparacion y su utilizacion farmaceutica como inhibidores de cinasas | |
CY1111168T1 (el) | Παραγωγο βενζιμιδαζολιου και χρηση αυτου | |
RU2018109925A (ru) | Галогензамещенное гетероциклическое соединение | |
PE20090549A1 (es) | Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta | |
EA200802052A1 (ru) | 2-(пиридин-2-ил)-пиримидины в качестве фунгицидов | |
RU2017134379A (ru) | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 | |
EA201290383A1 (ru) | Производные пиридинопиридонов, их получение и применение в терапии | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
RU2015148766A (ru) | Комбинации лигандов альфа-2 адренорецептора и сигма рецептора | |
AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
PE20100052A1 (es) | Derivados de 3-oxoisoindolin-1-carboxamida como inhibidores de los canales de sodio | |
MD4215C1 (ro) | Inhibitor al leucemiei mieloide umane în bază de N-(4-(5-(piridin-2-il)-4,5-dihidro-1H-pirazol-3-il)fenil)-2-(piridin-2-ilmetilen)-hidrazincarbotioamidă | |
EA201000604A1 (ru) | Новые производные имидазола | |
MX2016003630A (es) | Compuestos heterociclicos de n-acilimino. | |
TW200626007A (en) | Material for electroluminescent element and electroluminescent element |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |